BCL2AETooL
Interactive Tool for Managing Adverse Events Associated With BCL-2 Inhibitors in Hematologic Malignancies

Released: August 23, 2024

Expiration: August 22, 2025

Instructions

This Interactive Decision Support Tool provides treatment recommendations from 4 experts based on the specific malignancy and BCL-2 inhibitor therapy-related AE you enter in the tool. It is recommended that you have as much information as possible available before you begin.

You will be prompted to provide specific information about your patient including type of malignancy, current or future treatment planned with BCL-2 inhibitor therapy, AE and grade.

Click on your selections. Your choices can be changed at any time simply by selecting the [change] icon by the question you want to change and entering a new choice.

Additional information on each variable/characteristic and why it is important for making management decisions is available by clicking on the [i] icon after each selection.

When all patient characteristics are entered, you will be asked to select the management option you are currently planning. Once that information is entered, you can click on Submit Patient Case to view the expert recommendations.

After reviewing your case-specific recommendations, you will be asked brief questions about how the recommendations influenced your decision-making. You will then be able to enter a new case scenario by clicking the Start New Case button.

You will be able to print/download the recommendations along with a summary of the patient characteristics and selected therapy you entered by clicking the Case Summary button and view the Additional Considerations section covering additional information on dosing, dose adjustment, and TLS risk stratification and mitigation strategies.

Access to and use of this Interactive Decision Support Tool titled, “Interactive Tool for Managing Adverse Events Associated With BCL-2 Inhibitors in Hematologic Malignancies” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate clinicians on optimal management choices for adverse events associated with BCL-2 inhibitor therapy in AML, CLL, or SLL. The information provided is based on NCCN guideline recommendations, prescribing information for venetoclax, and expert guidance from Farrukh Awan, MD, MS, MBA; Courtney DiNardo, MD, MSCE; Daniel A. Pollyea, MD, MS; and Caitlin R. Rausch, PharmD, BCOP.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Interactive Tool for Managing Adverse Events Associated With BCL-2 Inhibitors in Hematologic Malignancies” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2024 Clinical Care Options, LLC. All rights reserved.

Program Content